A 38-year-old woman undergoes an interscalene block for right shoulder arthroscopy under general anesthesia. The anesthesiologist injects 20 mL of 0.5% bupivacaine. Five minutes after injection, the patient develops sudden onset tonic-clonic seizures followed by bradycardia (HR 42/min), hypotension (BP 78/48 mmHg), and a prolonged QRS complex (140 ms) on the monitor. Immediate measures are initiated including airway management, 100% oxygen, and seizure control. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis: Systemic Local Anesthetic Toxicity (SLAT) ### Pathophysiology Bupivacaine is a long-acting amide local anesthetic with high lipophilicity and cardiotoxicity potential. At plasma concentrations >4 mcg/mL, it causes: 1. **CNS toxicity first** — seizures, altered consciousness 2. **Cardiovascular toxicity** — arrhythmias, profound hypotension, cardiac arrest (bupivacaine causes more severe CV collapse than lidocaine) The clinical presentation here is classic: seizures followed by cardiovascular collapse (bradycardia, hypotension, QRS prolongation). ### Management Algorithm for SLAT ```mermaid flowchart TD A[Local Anesthetic Toxicity Suspected]:::outcome --> B[Stop injection, call for help]:::action B --> C[Airway management + 100% O2]:::action C --> D[Seizure control: benzodiazepines/propofol]:::action D --> E{Cardiovascular collapse?}:::decision E -->|Yes| F[Lipid Emulsion Therapy]:::action E -->|No| G[Supportive care + monitoring]:::action F --> H[20% Lipid: 1.5 mL/kg bolus IV]:::action H --> I[Infusion: 0.25 mL/kg/min]:::action I --> J[Repeat bolus q5min if CV instability persists]:::action J --> K[Max cumulative dose: 10-12 mL/kg over first 30 min]:::action K --> L[ECMO/CPB if refractory]:::urgent ``` ### Why Lipid Emulsion Works **Key Point:** Lipid emulsion therapy is the **definitive antidote** for severe bupivacaine toxicity, especially with cardiovascular collapse. - **Mechanism:** Lipophilic local anesthetics partition into the lipid phase, reducing free plasma concentration - **Onset:** Rapid reversal of cardiac arrhythmias and hemodynamic collapse (within minutes) - **Evidence:** ASRA guidelines (2018) recommend lipid emulsion as first-line for SLAT with cardiovascular instability ### Dosing Protocol | Phase | Dose | Interval | |-------|------|----------| | **Bolus** | 1.5 mL/kg of 20% lipid IV | Once | | **Infusion** | 0.25 mL/kg/min IV | Continuous | | **Repeat bolus** | 1.5 mL/kg | Every 5 min if CV instability persists (max 2 additional) | | **Maximum cumulative** | 10–12 mL/kg | Over first 30 minutes | **High-Yield:** In this case, the patient has already received seizure control (implied by "seizure control" in the stem) and airway management. The next critical step is lipid emulsion to reverse the profound cardiovascular collapse (bradycardia, hypotension, QRS prolongation). ### Clinical Pearl **Bupivacaine cardiotoxicity is notoriously resistant to standard ACLS.** Patients may require prolonged resuscitation (>1 hour) with lipid emulsion + CPR before return of spontaneous circulation. Do NOT abandon resuscitation efforts early. ### Why Not Sodium Bicarbonate or Amiodarone? - **Bicarbonate** may worsen hyperkalemia (local anesthetics cause K+ efflux); it is NOT first-line for SLAT - **Amiodarone** is used for arrhythmias refractory to lipid therapy, not as initial management - **Propofol** is contraindicated in lipid emulsion therapy (additional lipid load; also propofol is itself lipophilic and may compete for lipid binding) [cite:Miller's Anesthesia 8e Ch 16]